Lyka Labs reported a consolidated net loss of ₹10.58 crore for FY26, a shift from a profit in the previous year. A significant ₹23.01 crore impairment charge on its subsidiary impacted standalone results. The company is expanding capacity and entering new segments.
Lyka Labs Reports FY26 Net Loss of ₹10.58 Crore Amidst Impairment Charge
Lyka Labs Ltd has reported a consolidated net loss of ₹10.58 crore for the financial year ended March 31, 2026. This marks a significant downturn from a net profit of ₹8.11 crore in the comparable period of FY25. The company's consolidated revenue also saw a decline, falling to ₹131.94 crore from ₹140.73 crore in the previous fiscal year.
Reader Takeaway: Impairment charge drives loss; future growth hinges on expansion and new ventures.
What just happened
The company's standalone net loss for FY26 was substantially higher at ₹32.43 crore. This was largely due to an exceptional impairment charge of ₹23.01 crore. This charge relates to the company's investment in and outstanding loans provided to its subsidiary, Lyka BDR International Limited.
Why this matters
The shift to a consolidated net loss and the significant impairment charge will be a concern for investors. While the company is pursuing strategic growth initiatives, the immediate financial impact of the impairment and increased debt levels needs careful monitoring. The successful execution of expansion plans and diversification into new areas like Gynaecology and Assisted Reproductive Technology (ART) will be crucial for future profitability.
The backstory
Lyka Labs has been working on expanding its business. The company re-entered the animal healthcare segment in 2023. Recently, the National Company Law Tribunal (NCLT), Ahmedabad Bench, sanctioned the amalgamation of Lyka Export Limited with Lyka Labs Limited, effective March 16, 2026, aiming to streamline operations.
What changes now
Lyka Labs is actively investing in its future. A new division, 'FertiNova', has been launched to focus on Gynaecology and ART. Furthermore, the company is enhancing its lyophilisation capacity by 50%, with completion expected in 2026, targeting entry into regulated European markets. The debt-to-equity ratio has risen to 0.58 from 0.33, indicating increased leverage due to new loans for working capital.
Risks to watch
Lyka Labs faces ongoing legal and tax disputes. These include demands under the Drug Price Control Order (₹6.81 crore) and sales tax matters (e.g., ₹4.12 crore for Maharashtra sales tax). Unfavorable outcomes in these litigations could lead to significant financial liabilities. The rising debt-to-equity ratio also presents a watch point for solvency.
Peer comparison
(No direct peer comparison data available in the filing.)
Context metrics (time-bound)
Consolidated Revenue (FY26): ₹131.94 crore vs ₹140.73 crore (FY25)
Consolidated Net Loss (FY26): ₹(10.58) crore vs ₹8.11 crore (FY25)
Standalone Net Loss (FY26): ₹(32.43) crore
Exceptional Impairment Charge: ₹23.01 crore
Debt-to-Equity Ratio (FY26): 0.58 vs 0.33 (FY25)
What to track next
Investors should monitor the company's progress in its new therapeutic areas, the success of its lyophilisation capacity expansion, and its ability to manage increasing debt. The resolution of ongoing tax and legal disputes will also be a key factor.